Latest Innovation News

Arovella Therapeutics has secured TGA confirmation to advance its Phase 1 trial of ALA-101 in Australia via the efficient Clinical Trial Notification pathway, following FDA clearance in the US.

Image Resources NL is set to record significant non-cash impairments totalling around A$61 million in its 2025 financial results, reflecting challenges from weaker mineral sands prices and a stronger Australian dollar.

BlinkLab has completed onboarding its tenth and final clinical site for its pivotal FDA 510(k) trial of an AI-powered autism diagnostic aid, setting the stage for patient enrolment to begin this month.

Environmental Clean Technologies Limited has agreed to sell part of its Yallourn Property for $1.3 million, marking a clear pivot from its original hydrogen refinery plans. The sale proceeds will support ongoing technology development.

Renascor Resources has completed construction of its Purified Spherical Graphite demonstration facility in Adelaide, marking a pivotal step towards commercialising its innovative HF-free purification process for battery anode materials.

Green360 Technologies has landed a $3 million federal grant to advance Eco-Clay, a low-carbon cement alternative, aiming to decarbonise Australia's construction sector.

Eden Innovations reports a robust 65% increase in US OptiBlend revenue for FY2026 to date, driven by rising demand from data centres seeking cost-effective, lower-emission backup power solutions.

Ovanti Limited is reshaping its future with a strategic shift from its BNPL roots to a global financial Super App, exiting legacy US operations to focus on innovation and international expansion.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

Calix Limited has successfully completed the first milestone of its ARENA grant for the Zesty Green Iron Demonstration Project, unlocking a $2 million payment and marking a key step forward in its industrial decarbonisation efforts.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.